CureVac’s Fate Hangs in the Balance as Shareholders Vote on BioNTech Takeover
Published on 11/18/2025 at 13:39 | Redaktion boerse-global.de
The independent existence of CureVac could soon be a chapter in corporate history. On November 25, shareholders will convene in Amsterdam for an extraordinary general meeting, facing a definitive vote on the German biotech firm’s future. The central item on the agenda is a proposed acquisition by rival BioNTech, valued at approximately $1.25 billion. The prevailing sentiment among market observers is not if the Tübingen-based company will be absorbed by its mRNA competitor, but when the transaction will be finalized.
This pivotal moment follows the commencement of BioNTech’s public share exchange offer on October 22. The bid, which targets all outstanding CureVac shares, is structured on Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
